Fluvastatin prevents oxidized low-density lipoprotein-induced injury of renal tubular epithelial cells by inhibiting the phosphatidylinositol 3-kinase/Akt-signaling pathway

Journal of Nephrology

Volumn 19, Issue 3, 2006, Pages 286-295

  Chu, Guili ^a   Jia, R ^a   Yang, D ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; LEUCINE; MEVALONIC ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA1; WORTMANNIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLE DERIVATIVE; LOW DENSITY LIPOPROTEIN; MONOUNSATURATED FATTY ACID; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL CELL; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTER; KIDNEY TUBULE CELL; KIDNEY TUBULE EPITHELIUM; NONHUMAN; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CELL LINE; CULTURE TECHNIQUE; EPITHELIUM CELL; HUMAN; KIDNEY PROXIMAL TUBULE; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE; EPITHELIAL CELLS; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; KIDNEY TUBULES, PROXIMAL; LIPOPROTEINS, LDL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; SIGNAL TRANSDUCTION;

EID: 33749069084     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999; 56: 393-405.
2. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-â by anti-TGF-â antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996; 45: 522-30.
3. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor ? is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993; 90: 1814-8.
4. Muhlfeld AS, Spencer MW, Hudkins KL, Kirk E, LeBoeuf RC, Alpers CE. Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice. Kidney Int 2004; 66: 1393-1402.
5. Klahr S, Tripathy K, Bolanos O. Qualitative and quantitative analysis of urinary lipids in the nephrotic syndrome. J. Clin Invest 1967; 46: 1475-81.
6. Shore VG, Forte T, Licht H, Lewis SB. Serum and urinary lipoproteins in the human nephrotic syndrome: evidence for renal catabolism of lipoproteins. Metabolism 1982; 31: 258-68.
7. Pollak, Robinson K. Sequestration and excretion of high density and low-density lipoproteins by the kidney in human nephrotic syndrome. Artery 1979; 6: 108-121.
8. Ong AC, Moorhead JF. Tubular lipidosis: epiphenomenon or pathogenic lesion in human renal disease? Kidney Int 1994; 45: 753-62.
9. Schlondorff D. Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis 1993; 22: 72-82.
10. Daugherty A, Dunn JL, Rateri DL, Heinecker JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94: 437-44.
11. Syrianen J, Mustonen J, Pasternack A. Hypertrigliceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000; 15: 34-42.
12. Mulec H, Johnsen SA, Wiklund O, Bjorck S. Cholesterol: A renal risk factor in diabetic nephropathy? Am J Kidney Dis 1993; 22: 196-201.
13. Seibold S, Schurle D, Heinloth A, Wolf G, Wagner M, Galle J. Oxidized LDL induces proliferation and hypertrophy in human umbilical vein endothelial cells via regulation of p27Kip1 expression: role of RhoA. J Am Soc Nephrol 2004; 15: 3026-34.
14. Kita T, Kume N, Minami M, Hayashida K, Murayama T, Sano H, Moriwaki H, Kataoka H, Nishi E, Horiuchi H, Arai H, Yokode M. Role of oxidized LDL in atherosclerosis. Ann N Y Acad Sci 2001; 947: 199-205.
15. Lee HS. Oxidized LDL, glomerular mesangial cells and collagen. Diabetes Res Clin Pract 1999; 45: 117-22.
16. Nishida Y, Oda H, Yorioka N. Effect of lipoproteins on mesangial cell proliferation. Kidney Int 1999; 71: S51-3.
17. Agarwal A, Balla J, Balla G, Croatt AJ, Vercellotti GM, Nath KA. Renal tubular epithelial cells mimic endothelial cells upon exposure to oxidized LDL. Am J Physiol 1996; 271: F814-23.
18. Bussolati B, Deregibus MC, Fonsato V, Doublier S, Spatola T, Procida S, DiCarlo F, Camussi G. Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol 2005; 16: 1936-47.
19. Galle J, Wanner C. Oxidized LDL and Lip (a): preparation, modification, and analysis. In Armstrong D (Ed). Free radical and antioxidant protocols. Totowa, NJ: Humana Press 1998; 119-30.
20. Awazu M, Omori S, Ishikura K, Hida M, Fujita H. The lack of cyclin kinase inhibitor p27 (Kip1) ameliorates progression of diabetic nephropathy. J Am Soc Nephrol 2003; 14: 699-708.
21. Lan Y, Zhou Q, Wu ZL. NF-kappa B involved in transcription enhancement of TGF-beta1 induced by ox-LDL in rat mesangial cells. Chin Med J 2004; 117: 225-30.
22. Roh DD, Kamanna VS, Kirschenbaum MA. Atherogenic lipoproteins enhance murine cortical epithelial cell fibronectin protein synthesis and gene expression. Am J Nephrol 1998; 18: 83-8.
23. Wu Z, Zhou Q, Lan Y, Wang Y, Xu X, Jin H. AP-1 complexes mediate oxidized LDL-induced overproduction of TGF-beta (1) in rat mesangial cells. Cell Biochem Funct 2004; 22: 237-47.
24. Wolf G, Neilson EG. Angiotensin II induces cellular hypertrophy in cultured murine tubular cells. Am J Physiol 1990; 259: F768-77.
25. Wolf G, Neilson EG, Goldfarb S, Ziyadeh FN. The influence of glucose concentration on angiotensin IIinduced hypertrophy of proximal tubular cells in culture. Biochem Biophys Res Commun 1991; 179: 902-9.
26. Wolf G, Killen PD, Neilson EG. Intracellular signalling of transcription and secretion of type IV collagen after angiotensin II-induced cellular hypertrophy in cultured proximal tubular cells. Cell Regul 1991; 2: 219-27.
27. Rocco M, Chen Y, Goldfarb S, Ziyadeh FN. Elevated glucose stimulates TGF-â gene expression and bioactivity in proximal tubule. Kidney Int 1992; 41: 107-14.
28. Wolf G, Zahner G, Mondorf U, Schoeppe W, Stahl RA. Angiotensin II stimulates cellular hypertrophy of LLCPK1 cells through the AT1 receptor. Nephrol Dial Transplant 1993; 8: 128-33.
29. Wolf G, Mueller E, Stahl RA, Ziyadeh FN. Angiotensin II induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-â. J Clin Invest 1993; 92: 1366-72.
30. Wolf G, Ziyadeh FN, Schroeder R, Stahl RA. Angiotensin II stimulates expression of transforming growth factor type II in cultured mouse proximal tubular cells. J Mol Med 1999; 77: 556-64.
31. Senthil D, Choudhury GG, McLaurin C, Kasinath BS. Vascular endothelial growth factor induces protein synthesis in renal epithelial cells: a potential role in diabetic nephropathy. Kidney Int 2003; 64: 468-79.
32. Hixon ML, Muro-Cacho C, Wagner MW, Obejero-Paz C, Millie E, Fujio Y, Kureishi Y, Hassold T, Walsh K, Gualberto A. Akt1/PKB upregulation lead to vascular smooth muscle cell hypertrophy and polyploidyization. J Clin Invest 2000; 10: 1011-20.
33. Auge N, Garcia V, Maupas-Schwalm F, Levade T, Salvayre R, Negre-Salvayre A. Oxidized LDL-induced smooth muscle cell proliferation involves the EGF receptor/PI-3 kinase/Akt and the sphingolipid signaling pathways. Arterioscler Thromb Vasc Biol 2002; 22: 1990-5.
34. Hundal RS, Salh BS, Schrader JW, Gomez-Munoz A, Duronio V, Steinbrecher UP. Oxidized low density lipoprotein inhibits macrophage apoptosis through activation of the PI 3-kinase/PKB pathway. J Lipid Res 2001; 42: 1483-91.
35. Li DY, HJ. Chen, J L Mehta. Statins inhibit oxidized LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reductionin PKB phosphorylation. Cardiovasc Res 2001; 52: 130-5.
36. Nakagawa T, Yasuda T, Hoshikawa H, Shimizu M, Kakinuma T, Chen M, Masaki T, Nakamura T, Sawamura T. LOX-1 expressed in cultured rat chondrocytes mediates oxidized LDL-induced cell death-possible role of dephosphorylation of Akt. Biochem Biophys Res Commun 2002; 299: 91-7.
37. Auge N, Garcia V, Maupas-Schwalm F, Levade T, Salvayre R, Negre-Salvayre A. Oxidized LDL-induced smooth muscle cell proliferation involves the EGF receptor/PI-3 kinase/Akt and the sphingolipid signaling pathways. Clin Exp Pharmacol Physiol 2005; 32: 224-9.
38. Chavakis E, Dernbach E, Hermann C, Mondorf UF, Zeiher AM, Dimmeler S. Oxidized LDL inhibits vascular endothelial growth factor-induced endothelial cell migration by an inhibitory effect on the Akt/endothelial nitric oxide synthase pathway. Circulation 2001; 103: 2102-7.
39. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor â-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000; 275: 36803-10.
40. Grandaliano G, Biswas P, Choudhury GG, Abboud HE. Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int 1993; 44: 503-8.
41. Lan Y, Zhou Q, Wu ZL. NF-kappa B involved in transcription enhancement of TGF-beta1 induced by oxLDL in rat mesangial cells. Chin Med J 2004; 117: 225-30.
42. Vrtovsnik F, Couette S, Prie D, Lallemand D, Friedlander G. Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p2lras activated, AP-1-dependent pathway. Kidney Int 1997; 52: 1016-27.
43. Oda H, Kasiske BL, O'Donnell MP, Keane WF. Effects of lovastatin on expression of cell cycle regulatory proteins in vascular smooth muscle cells. Kidney Int Suppl 1999; 71: S202-5.
44. Ogata Y, Takahashi M, Takeuchi K. Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy. J Cardiovasc Pharmacol 2002; 40: 907-15.
45. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, Takeshita A. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 105: 868-73.
46. Cerezo-Guisado MI, Garcia-Marin LJ, Lorenzo MJ, Bragado MJ. Lovastatin inhibits the growth and survival pathway of phosphoinositide 3-kinase/protein kinase B in immortalized rat brain neuroblasts. J Neurochem 2005; 94: 1277-87.
47. Prasad R, Giri S, Nath N, Singh I, Singh AK. Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-?B pathway by lovastatin limits endothelial-monocyte cell interaction. J Neurochem 2005; 94: 204-14.
48. Wolfrum S, Dendorfer A, Schutt M, Weidtmann B, Heep A, Tempel K, Klein HH, Dominiak P, Richardt G. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 2004; 44: 348-55.